Vanda Pharmaceuticals (VNDA) Gross Profit (2010 - 2026)

Vanda Pharmaceuticals has reported Gross Profit for 14 years, with the latest figure at $48.6 million in Q1 2026.

• Quarterly Gross Profit rose 4.38% year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.1 million (up 7.97% YoY) and the FY2025 annual result came in at $203.1 million, up 8.32% from the prior year.
• Gross Profit retreated to $48.6 million in Q1 2026 per VNDA's latest filing, from $53.4 million in the prior quarter.
• Over five years, Gross Profit peaked at $59.0 million in Q3 2022 and troughed at $35.8 million in Q3 2023.
• A 5-year average of $49.8 million and a median of $49.9 million in 2025 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2023 and 2024: Gross Profit tumbled 39.4% in 2023, then gained 26.15% in 2024.
• Over 5 years, Gross Profit stood at $58.2 million in 2022, then declined by 28.21% to $41.8 million in 2023, then advanced by 21.01% to $50.6 million in 2024, then climbed by 5.51% to $53.4 million in 2025, then decreased by 9.04% to $48.6 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $48.6 million, $53.4 million, and $53.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.